AU2023264918A1 - Cyclic compound having selective kras inhibitory effect on hras and nras - Google Patents

Cyclic compound having selective kras inhibitory effect on hras and nras Download PDF

Info

Publication number
AU2023264918A1
AU2023264918A1 AU2023264918A AU2023264918A AU2023264918A1 AU 2023264918 A1 AU2023264918 A1 AU 2023264918A1 AU 2023264918 A AU2023264918 A AU 2023264918A AU 2023264918 A AU2023264918 A AU 2023264918A AU 2023264918 A1 AU2023264918 A1 AU 2023264918A1
Authority
AU
Australia
Prior art keywords
trifluoromethyl
phenyl
ethyl
methylpropyl
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023264918A
Other languages
English (en)
Inventor
Satoshi Hashimoto
Ryuji Hayashi
Mirai Kage
Hatsuo Kawada
Tomoya Kotake
Yuya Morita
Koji Takano
Minoru Tamiya
Yuma Wakamiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2023264918A1 publication Critical patent/AU2023264918A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2023264918A 2022-05-06 2023-05-02 Cyclic compound having selective kras inhibitory effect on hras and nras Pending AU2023264918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022076449 2022-05-06
JP2022-076449 2022-05-06
PCT/JP2023/017112 WO2023214576A1 (ja) 2022-05-06 2023-05-02 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物

Publications (1)

Publication Number Publication Date
AU2023264918A1 true AU2023264918A1 (en) 2025-01-09

Family

ID=88646541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023264918A Pending AU2023264918A1 (en) 2022-05-06 2023-05-02 Cyclic compound having selective kras inhibitory effect on hras and nras

Country Status (15)

Country Link
US (2) US12410212B2 (https=)
EP (1) EP4512818A1 (https=)
JP (1) JP7823181B2 (https=)
KR (1) KR20250008758A (https=)
CN (1) CN119731195A (https=)
AR (1) AR129238A1 (https=)
AU (1) AU2023264918A1 (https=)
CA (1) CA3256645A1 (https=)
CL (1) CL2024003354A1 (https=)
CO (1) CO2024016293A2 (https=)
IL (1) IL316253A (https=)
MX (1) MX2024013352A (https=)
PE (1) PE20251872A1 (https=)
TW (1) TW202406927A (https=)
WO (1) WO2023214576A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
WO2018225851A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
US12404299B2 (en) 2019-11-07 2025-09-02 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound comprising highly sterically hindered amino acid
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
TW202434275A (zh) * 2022-11-09 2024-09-01 日商中外製藥股份有限公司 含有相對於ｈｒａｓ與ｎｒａｓ具有選擇性ｋｒａｓ抑制作用之環狀化合物的醫藥組成物
KR20250160895A (ko) 2023-03-20 2025-11-14 추가이 세이야쿠 가부시키가이샤 고리형 펩타이드의 공결정을 제조하는 방법
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025162428A1 (en) * 2024-01-29 2025-08-07 Syneron Technology Co. Ltd. Cyclic peptide compounds and compositions as ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547852A (zh) * 2024-03-13 2025-12-16 日商中外製藥股份有限公司 具有環狀結構的胜肽化合物的製造方法
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6239979B2 (ja) 2011-03-04 2017-11-29 ニューヨーク・ユニバーシティ Ｒａｓの調節因子としての水素結合代替大環状分子
EP2721048A1 (en) 2011-06-16 2014-04-23 Lonza Ltd A process for extraction of peptides and its application in liquid phase peptide synthesis
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
DK3269809T3 (da) 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2017150732A1 (ja) 2016-03-03 2017-09-08 中外製薬株式会社 チオール基をアミノ基近傍に有するアミノ酸をｎ末端に持つ非環状ペプチド－核酸複合体、そのライブラリー、およびそれから誘導される環状ペプチド－核酸複合体ライブラリーの製造方法
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
EP4039250A1 (en) 2016-12-28 2022-08-10 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
JP7232758B2 (ja) 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2018225851A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
EP3725796A4 (en) 2017-12-15 2021-09-15 Chugai Seiyaku Kabushiki Kaisha METHOD FOR MANUFACTURING PEPTIDE AND METHOD FOR PROCESSING BASES
GB201805088D0 (en) 2018-03-28 2018-05-09 Univ Warwick Macrocyclization of peptidomimetics
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
JP7568510B2 (ja) 2018-11-30 2024-10-16 中外製薬株式会社 ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
WO2020138336A1 (ja) 2018-12-26 2020-07-02 中外製薬株式会社 コドン拡張のための変異ｔＲＮＡ
KR20210139366A (ko) 2019-03-15 2021-11-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
US12404299B2 (en) 2019-11-07 2025-09-02 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound comprising highly sterically hindered amino acid
JP7744244B2 (ja) 2019-12-26 2025-09-25 中外製薬株式会社 翻訳用組成物及びペプチドの製造方法
JP7709920B2 (ja) 2019-12-27 2025-07-17 中外製薬株式会社 ペプチド化合物の合成法
EP4144747A4 (en) 2020-06-03 2024-05-29 Chugai Seiyaku Kabushiki Kaisha EFFICIENT PEPTIDE CONDENSATION PROCESS FOR DIFFICULT SEQUENCES
TW202208623A (zh) 2020-06-25 2022-03-01 日商中外製藥股份有限公司 具有經改變之遺傳密碼表的轉譯系統
US20230391818A1 (en) 2020-11-05 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Peptide synthesis method for suppressing defect caused by diketopiperazine formation
JPWO2022138891A1 (https=) 2020-12-25 2022-06-30
US20240067674A1 (en) 2020-12-28 2024-02-29 Chugai Seiyaku Kabushiki Kaisha Method for loading amino acid on resin for solid-phase synthesis
KR102666765B1 (ko) 2021-05-07 2024-05-16 추가이 세이야쿠 가부시키가이샤 환상 펩타이드 화합물의 의약 용도
AU2022270498A1 (en) 2021-05-07 2023-10-05 Chugai Seiyaku Kabushiki Kaisha Preparation containing cyclic peptide compound and method for producing same
AR125796A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras
WO2022234639A1 (ja) 2021-05-07 2022-11-10 中外製薬株式会社 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法
MX2024008002A (es) 2021-12-28 2024-07-12 Chugai Pharmaceutical Co Ltd Metodo para producir n-alquilaminoacido y peptido que incluye n-alquilaminoacido.
MX2024008358A (es) 2022-01-21 2024-07-19 Chugai Pharmaceutical Co Ltd Medicina para tratar o prevenir el cancer.
US20250353875A1 (en) 2022-05-02 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Peptide synthesis method for suppressing defect caused by diketopiperazine formation

Also Published As

Publication number Publication date
KR20250008758A (ko) 2025-01-15
US20250230193A1 (en) 2025-07-17
WO2023214576A1 (ja) 2023-11-09
US12410212B2 (en) 2025-09-09
PE20251872A1 (es) 2025-07-22
TW202406927A (zh) 2024-02-16
CL2024003354A1 (es) 2025-03-21
JPWO2023214576A1 (https=) 2023-11-09
JP7823181B2 (ja) 2026-03-03
CA3256645A1 (en) 2025-04-23
CN119731195A (zh) 2025-03-28
CO2024016293A2 (es) 2025-02-24
US20250051394A1 (en) 2025-02-13
AR129238A1 (es) 2024-07-31
MX2024013352A (es) 2024-12-06
IL316253A (en) 2025-01-01
EP4512818A1 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
AU2023264918A1 (en) Cyclic compound having selective kras inhibitory effect on hras and nras
Coxall et al. Inter-ligand reactions: in situ formation of new polydentate ligands
Kickham et al. Simultaneous First-and Second-Sphere Coordination. Organopalladium Metalloreceptors for Water, Ammonia, Amines, Hydrazine, and the Hydrazinium Ion
US5220106A (en) Organic non-quaternary clathrate salts for petroleum separation
McCollum et al. Bimetallic reactivity. General synthesis of binucleating macrocyclic ligands containing 6-and 4-coordinate sites
WO2004080974A1 (en) A purification method of ionic liquids to obtain their high purity
Giordano et al. The crystal structures of the monoclinic and orthorhombic forms of zinc (II) n-butylphenylphosphinate polymer
KR20220073508A (ko) 우수한 용해도를 가지는 촉매를 이용한 이종 선형 카보네이트를 제조하는 방법
Asgedom et al. Oxovanadium (V) Schiff base complexes of trishydroxymethylaminomethane with salicylaldehyde and its derivatives: synthesis, characterization and redox reactivity
Chandler et al. Synthesis, characterization, and reactivity of lead (II) glycolate complexes
Puar et al. Orientation of the sulfoxide bond as a stereochemical probe. Synthesis and proton and carbon-13 NMR of substituted thiopyrano [4, 3-c] pyrazoles
Koneczny et al. Titanium complexes with unsymmetrically substituted imidazolin-2-iminato ligands
Choi et al. (Thioallyl) iron tricarbonyl complexes
SU1121284A1 (ru) Способ получени пластичных парафинов
PL141866B1 (en) Method of obtaining 1,8-dihydroxy-10-ocyl-9-antrones
EP2678344B1 (de) Cyclopropenyl-yliden stabilisierte phospheniumkationen
Fox et al. Asymmetric synthesis of cyclopropanes and dihydrofurans based on phosphine oxide chemistry
Ammon et al. The crystal and molecular structures of three isoquinoline derivatives: 1-chloro-3-hydroxyisoquinoline, 1-phenyl-2-methyl-3-isoquinolone and 2-(2', 6'-dichlorobenzyl)-1-isoquinolone
Willey et al. Reactions of ZrOCl2· 8H2O with carboxylic acids and thionyl chloride: crystal and molecular structures of K4 [Zr (mal) 4]· 2H2O and K4 [Zr (dipic) 3] 2· 13.5 H2O
Labadi et al. Thermal stability and crystal structure of bis (1, 2 ethanediol) zinc sulfate
Sanchez-Mendoza et al. Synthesis of Quinazoline Derivatives in the Presence of Titanium-Containing Solid Acid Nanoparticles
Mendoza-Espinosa Synthesis and characterization of a Bi 10 O 8 (OAr) 16 oxo-cluster supported by p-tert-butylcalix [5] arene ligands
US4100163A (en) Substituted 8-sulfonamidoquinolines
DE2437132B2 (de) Verfahren zur Herstellung von heterocyclischen Verbindungen
US3116309A (en) Heterocyclic compounds containing ring carbon, nitrogen and phosphorus or arsenic atoms and their preparation